Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PFNH detailed DD:
You'll find everything you need on this PFNH board:
http://www.siliconinvestor.com/subject.aspx?subjectid=55941
A incredible LIITLE 7 MILLIONS $
company that BEATS INTEL!
Think about it and Ask yourself how much it should be valued...
This is a undiscovered jewel and truely a no brainer situation...just like BIPH and MIVT.
I truely believe that the stock will take of itself in the coming months.
Now read this:
Perfisans Announces Test Results Showing its ENA1001 as the Fastest Networking Chip Available in the Market Today
Internal test shows that the ENA1001 accelerator chip exceeds industrial gigabit transmit and receive data throughput and speed expectation, making Perfisans' chip a true gigabit Ethernet Accelerator in terms of both speed and performance.
To-Hon Lam, Perfisans CEO and co-founder proudly announces that "our internal test has shown that every board using ENA1001 tested under various conditions has delivered over 945Mbps speed. These test results show that this is the fastest chip currently available on the market today. No other product comes closer in speed and performance; Our internal tests using third parties throughput performance software have shown that our chip beats super high-end multi-hundred dollar chip performance from brand-name companies such as Intel (NASDAQ:INTC - News), Broadcom (NASDAQ:BRCM - News) and Marvell (NASDAQ:MRVL - News)." The ENA1001 not only beats out competitors (based on our internal tests) in speed performance but in price as well.
"This is a major milestone for Perfisans," said To-Hon Lam, Perfisans CEO and co-founder. "The fact that we have entered the market with an industry performance leading product in so short a development time frame, and with minimal capital expenditure, is a significant measure of the excellence of our team, and the efficiency of our unique chip architecture."
The ENA1001 has exceeded all performance expectations in Perfisans internal laboratory tests.
Bok Wong Perfisans VP of Business Development and co-founder said:
"With our production-ready design kit, the chip is set to reap substantial market share, tapping into the explosive growth of the networks and telecommunications markets." Bok Wong adds, "These internal test results will only enhanced our sales efforts and we look forward on building onto this momentum."
NEOP analysts research
spelmanresearch.com
----------------------
All companies research report bellow:
http://www.spelmanresearch.com/investment-research.html?POPUP_ID_R=548
NEOP initial report june 2004:
http://www.spelmanresearch.com/reports/205.pdf
Dutton associates:
------------------------
09/07/2005
http://www.jmdutton.com/research/neop/reports/neop_report_090705.pdf
verylongonmfys
you should take a look at a poster on PFNH board
This is misleading information
This guy should be banned from the board
http://www.investorshub.com/boards/read_msg.asp?message_id=7973891
JustForFun7 you're lying!
be carefull with your misleading information!!
They've never ever said that 8 million was their goal last year.
I'm not thinking about selling MEMY at all at this point. Just look at the incredible volume the stock is trading compared to its historical volume. I see at least $4.5 on the horizon,short term.
The way the stock is acting, not closing at the high of the day, is quite bullish, because this way, altough it opens higher on the next day, it doesn't do it on a gap up.
Profit taking is taking place as xwhois did, but the stock holds and continues to move higher. I have a 35% profit on MEMY and I will let it grow, the trend is my friend.
'Trade_4_Money'
Sorry but i disagree.
no volume at all.
very nice accumulation today
PFNH intraday:
http://139.142.147.22/GifChartEngine.dll?interval_day=6&cus=0&indexSymbol=&securityType=...
PFNH 3 months charts:
http://139.142.147.218/StockChart_ImageOnly.dll?cus=0&co=ask&i_chart=0&inm=5&ind=2&a...
here we go!!
the trend won't stop ,in fact just starting!!
PFNH,JustForFun7 read this Letter to Shareholders
http://biz.yahoo.com/bw/050808/85381.html?.v=1
Perfisans Networks Releases Letter to Shareholders Updating its Business Developments for the Company
Monday August 8, 9:00 am ET
Gigabit Network Accelerator Semiconductor Company, Perfisans Networks Very "Up Beat" about Its 2005 Prospects
LOS ANGELES--(BUSINESS WIRE)--Aug. 8, 2005-- Perfisans Networks Corp. (OTCBB:PFNH - News), a next-generation fabless semiconductor company focused on the burgeoning Gigabit Ethernet market, releases today, its "Shareholder Update Letter" by its Chairman & CEO, "Mr. To Hon Lam."
Dear Fellow Shareholder,
2005 is turning out to be an exciting year for Perfisans. This letter will bring you up to date with respect to the Company's business and recent developments. In 2004, management focused on developing, refining, and beta testing the ENA1001 Gigabit Network Accelerator chip. A significant milestone was reached when internal tests show that our chip exceeds industrial gigabit transmit and receive data throughput and speed expectations, making Perfisans' chip a true gigabit Ethernet Accelerator in terms of both speed and performance. These results allow our product to stand above our competitors in performance while delivering a significant cost savings on price (in some cases as much as 70% lower than the price of any of its competitors).
In the first two quarters of 2005, Perfisans has made significant progress in the marketing and sales of the company's products as we continue to aggressively grow our business. The Company has successfully received blanket orders from DBL Technology Co. Ltd., eIDS Solutions (ASIA) Ltd., in China and Kelytech Corporation in the USA. Volume shipments of ENA1001 are scheduled to begin in the 3rd quarter of 2005, and the company expects to see revenue ramping upwards towards meeting its 2005 revenue projections of $8 million.
In June, the Company announced a partnership engagement with PC Partner for the manufacturing of its Gigabit Ethernet network interface cards (NIC). Immediately, PC Partner will produce several Network Interface Cards that Perfisans has slated for the market place. This includes the true Gigabit Ethernet single-port Network Interface Card (NIC) (part number ENA5031) incorporating the Perfisans ENA1001 chip. In another milestone event, the Company recently announced the network accelerator board order from Zhejiang Orient Fibersense Photonics Communication Company Limited (FSP). FSP expects to purchase a minimum $2.5 million worth of the network boards over the next twelve months.
According to IDC, OVUM Research, by 2008 over 90% of the computers manufactured will be equipped with gigabit network interface. Today, there are over one hundred million computers manufactured annually. This equates to a potential market for our chip of over one hundred million pieces: as our chips are positioned to be adaptable onto every motherboard shipped out by OEM's. We are now aggressively marketing our chips to network interface card manufacturers, motherboard manufacturers, and computer manufacturers and anticipate the signing of numerous orders before the year ends.
In addition to our current product lines, the Company is continuously engaged in further product development, thus always staying ahead of any potential competitor. Development is currently underway for the RDMA microchip technology, a PCI Express interface card, and a 10 Gigabit product. These products will carry the Company to the next level, ensuring we will always stay competitive for the future while showing the market place and the investment community alike that Perfisans has continued product flow and is not just dependant on initial product launches.
To our shareholders, customers, employees, and partners, we thank you for your continued confidence and support in our company, as we now turn the corner from a pure R&D company into a revenue generating operation: designing, producing and marketing leading edge products in the Gigabit Ethernet Accelerator products sector. We look forward to a very exciting 12 months ahead of us as we establish ourselves as the leading player in this sector.
Yours truly,
To-Hon Lam
Chairman and CEO
Perfisans Holdings Inc.
About Perfisans Holdings Inc.
Founded in 2001, Perfisans Holdings, Inc. is an emerging fabless semiconductor company focused on developing leading edge, cost-effective, system-on-chip (SOC) integrated circuits (IC) and delivering innovative solutions that address the performance needs of next generation network interface systems. Rapidly becoming recognized and endorsed by industry leaders for its innovative ASIC architectures, the Company's technologies have applications in data-telecommunication, storage networks, content delivery networks, broadband networks, and rich streaming media.
Commercial and private network systems that utilize Perfisans' true gigabit Ethernet accelerator products reward their operators with significantly faster network data throughput speeds, increased day-to-day operating efficiencies and enhanced bottom line performance. Enterprise operators also welcome Perfisans' full standards compliance and backward compatibility that makes possible significant systems performance upgrades to existing network systems at very low cost, by avoiding the necessity for operators to buy expensive additional equipment. In addition, Perfisans' unique, modular, micro-engine ASIC architectures yield industry leading performance in very small chip sizes, with low manufacturing costs. In contrast, leading competitive vendors have opted for over-kill, CPU intensive chip designs which deliver sub-par performance in costly, large chip sizes.
More information can be obtained from the Company's web site at www.perfisans.com.
I've dicovered a little PFNH
I believe this one will be a huge winner and it's very undervalued right now.
Here's the DD :
http://www.siliconinvestor.com/subject.aspx?subjectid=55941
thanks,'KeepingtheFaith3'
I tend to agree with you that it was the last opportunity to buy in the teens.
I believe PFNH will be in the .30's over the next trading days.
http://stockcharts.com/def/servlet/SharpChartv05.ServletDriver?chart=pfnh,uu[w,a]dhcayiay[dc][pb5!b1...
as i told you
i bought very recently at .17 and .18.
this stock could skyrocket in the next 12 months to 1.50 to 2 $.
Double bottom as expected!
KeepingtheFaith3
your technical and fundamental analysis are correct.
I wouldn't be surprised if PFNH goes down a little further
between .16 and .20.in the next trading days.
Just in case i've already placed a buy order at .18
I believe from this level it should rebound strongly.
'Trade_4_Money'
There's a post for you in your PFNH board!
could you reply
'Trade_4_Money' Nice to hear that news!
Is it your personal opinion that the CEO is signing contracts in China or the company told you this?
Do you know when the CEO will come back from China?
Thanks.
lentinman
I completely agree with you about CXTI!
A huge decline is imminent in my opinion.
A poster spoke about PKZ!Let's talk about it!
First it didn't go from 12 cents to 1.75$ but from a perfect 30 cents base.
Second,after the run up from the base of 30 cents to 1.75$(in 16 trading days)it went down nearly 60% yes 60% to 75 cents or so in only... 3 trading days!
Hre's the proof:
http://moneycentral.msn.com/investor/charts/chartdl.asp?Symbol=PKZ&ShowChtBt=Refresh+Chart&D...
Hre's the fundamentals story:
http://quicktake.morningstar.com/Stock/Income10.asp?Country=USA&Symbol=PKZ&stocktab=finance
'bob2feathers'
yes,you're welcome!
hweb,CXTI
i think this one will go to .90 to .95 before going up again.
Any opinion Hweb?
Thanks
you're welcome Guy
what do you think of CXTI short term,
are you still holding?
Guy oil price chart:
you'll find a lot of charts here:
http://www.stockhouse.com/commodities/index.asp
A good read regarding
PFNH technology:
Twenty years ago one chip ran your entire computer. Today you have specialist chips within your computer. The main CPU handles the majority of the processing. However, you may have a special graphics card with an associated graphics chip which helps alleviate the load on the main CPU.
You are looking at a picture of Adaptec's latest and greatest ethernet card. It contains a high tech chip which works on a specialized TCP/IP architecture known as TCP/IP Offload Engine or TOE (techies love acronyms for everything). Both Intel and Broadcom make a similar product.
This ethernet card comes with a highly specialized chip designed to handle the massive amounts of data which can flow in and out of your computer through your network- whether it be your high speed connection at home or your network at a place of business. Without this new high tech architecture, the main CPU helps process the data, which slows down everything else it should be working on. As more information flows through your network, the ethernet card becomes a much tighter bottleneck without the specialized board and chip.
You won't find this new high speed ethernet card in your typical $1,000 Dell computer. The reason is simple. It costs too much. If you go into your local Comp USA you will find that this new high speed ethernet card costs about $650. The one Dell puts in a $1,000 box runs about $60. The cost difference is mostly due to the price of the special high speed chip on the card.
According to Moore's law, processing speed doubles and the prices get cut in half every 18 months. Perfisans is in the business of making sure Mr. Moore's law lives on.
This is the Perfisans specialized microprocessor, more commonly known as a computer chip. It has been in development since 2001. $4.5 million has been invested in the development of this chip, and the majority of the experimentation was done in China, where $4.5 million could equate to $15 million in the US.
In early August Perfisans announced it had completed product development and is currently demonstrating the ACC-1001 Accelerator chip to networking companies world wide.
This is a specialized chip which is designed to be included in the architecture of an ethernet card. It is not faster than any other chip currently on the market, but it is considerably less expensive.
When installed in a desk top computer, processing speed will improve considerably. The smart NICs (network interface cards) will take up to 80% of TCP network processing overhead off network host computers. According to VP Steve Gormley “This frees the rest of the system to concentrate on pumping the payload data,”. “It's a powerful solution that provides meaningful cost-savings and other benefits to users of enterprise networks."
In short, your networked computer will be much faster with this chip on your ethernet card. The chip is so much cheaper that the Adaptec product with the TOE architecture we covered above could drop in cost from $650 to $65. If this is the case, this chip could end up on the cards which are included in the aforementioned $1,000 Dell box.
Today, after the market closed, Perfisans announced the first purchase order for its low cost accelerator chip. DBL Technology LTD, a maker of Voice-Over-Internet Protocol (VoIP) communications equipment based in Shenzhen, China, placed the initial order. DBL is an OEM for the enormous Taiwan and China communication markets.
When using VoIP technology, you are using your computer and the internet to talk over the telephone. Massive amounts of data must flow in and out of your ethernet connection as you talk. Therefore, this is one of the most ideal locations for a specialized chip as VoIP becomes more widely accepted.
Perfisans has now proven it has a bona fide low cost accelerator chip with the first purchase order. As more and more information flows in and out of your computer into your network, the need for low cost versions of these high speed chips will increase.
CXTI,ANY CHARTISTS here ?
I would appreciate very much a technical opinion
regarding CXTI short term.
Thanks
Astris Energi VP Finance Webcast
with www.TheGreenbaron.Com Now Available
Monday August 8, 1:40 pm ET
MISSISSAUGA, Ontario, Aug. 8, 2005 (PRIMEZONE) -- Astris Energi Inc. (OTC BB:ASRNF.OB - News), the world's leading alkaline fuel cell (AFC) technology company, announced today that Anthony Durkacz, VP of Finance of Astris Energi Inc., has conducted an exclusive webcast interview with the Green Baron so that ASRNF shareholders and the investment community can learn more about the current and future prospects of the company. The webcast was conducted by Evergreen Marketing Inc. and their subsidiary thegreenbaron.com and is now available for listening on The Green Baron Investors Society's Web site at http://www.thegreenbaron.com.
About Astris Energi Inc.
Astris is a late-stage development company committed to becoming the leading provider of affordable fuel cells and fuel cell generators internationally. Astris is commencing pilot production of its POWERSTACK(tm) MC250 technology in 2005. Astris is the only publicly traded company in North America focused exclusively on the, economically more favourable, alkaline fuel cell. Additional information is also available at the company's Web site at http://www.astris.ca.
Xenomcis Takes Aim at Amniocentisis With Transrenal DNA
Like many biotech breakthroughs, this particular technology has its roots in a 20 year old discovery. In 1986, Dr. Samuil Umansky was working for the Russian Health Ministry and doing clinical research on the radiation poisoning from the Chenobyl disaster.
Dr. Umansky discovered that radiation poison could be detected in urine. In order to be in urine, the radiation had to survive the kidney's highly effective cleansing process. The radiation poison was actually carried in the DNA. Until that discovery, the health sciences community never realized DNA could survive the kidneys and be passed out of the body in urine.
Hence the phrase "Transrenal DNA"- this is DNA which has been passed through the kidneys and can be detected and analyzed in urine.
Fast forward to 1996. Dr. Umansky is in the US, and has three patents concerning the use of Transrenal DNA. The three patents cover the applications of Transrenal DNA for use in transplantation, cancer, and early genetic testing of an unborn fetus.
The company, as it exists today, has been operating since last July. Despite being public since that time, XNOM has never made any effort to get its message out to investors. Therefore, you get the first look.
The company sees potential revenue generating applications in four areas for Transrenal DNA;
Cancer Detection
Infectious Disease Detection
Genetic Testing of an Unborn Fetus
Transplantation Monitoring
XNOM has spent the last nine months gathering data in its lab facility in Princeton, NJ. Ten highly qualified scientists work there on a full time basis doing the foundational research.
To date, XNOM has successfully harvested over 300 samples, otherwise known as "data points" in the industry. They have identified alien DNA (DNA not from the mother) in 119 urine samples from pregnant women, and analyzed data points from 200 samples of cancer patients in a study conducted with Thomas Jefferson University.
XNOM is destined to end up on the radar screens of many investors in the coming months. XNOM is preparing to start clinical trials for an FDA Approval of its first application in April. Since this is a non-invasive urine test, XNOM need only demonstrate the product works. They don't have the same stringent requirements you would have with a new drug. Therefore, XNOM anticipates it will only take about 2 years to obtain the FDA Approval. Clinical data will be made available to the public markets thoughout the course of the studies.
XNOM is taking aim at the barbaric "AMNIOCENTESIS" test performed on pregnant women worldwide. In the US alone there are approximately 6.2 million pregnancies each year. Of those, 10% to 15% are considered high risk for genetic diseases such as Downs Syndrome, Sickle Cell Anemia, Tay Sachs, and Huntingtons.
Currently, most pregnant women undergo a three panel test to prescreen prior to amniocentesis. If the doctor and patient decide to move forward, the amniocentesis test is performed.
An eight inch needle is inserted into the pregnant women's abdomen. Barbaric for a simple test. It penetrates the amniotic sack, and a small amount of amniotic fluid is withdrawn. The test is highly invasive and very dangerous. About 1% of tests performed lead to negative complications.
The amniotic fluid contains fetal DNA, which can be tested for genetic diseases.
XNOM expects to begin clinical trials in April for a test which could make amniocentesis obsolete. The test will be designed to replace the three panel test doctors recommend before considering amniocentesis. Most pregnant women who receive medical care in the US take this test.
XNOM's patented technology has the capability of identifying the fetal DNA in the mother's urine. Once identified, the DNA can be tested for genetic diseases.
Down the road XNOM intends to develop cancer and organ transplantation tests using the patented Transrenal DNA. In transplantation the patient has tissue with someone else's DNA. Early rejection can be detected in DNA changes. DNA from tumors can also be detected. Early detection of colon, liver, and pancreatic cancer is also possible with Transrenal DNA.
Today, after the market closed, XNOM announced an exciting development out of its joint venture with the National Institute for Infectious Diseases in Italy known as Lazzaro Spallanzani. XNOMannounced clinical results that demonstrate for the first time the ability to detect tuberculosis DNA in the urine of HIV infected patients. This could lead to the development of tests which provide significant advantages over the current tests.
There is a lot more to cover with this company. The management team led by CEO Randy White is exemplary. Randy White's resume is extraordinary in the biotech industry. Thomas Adams serves on the board- he was the CTO at stock market superstar Hybritech, and the founder and Chairman of Gen Probe, Inc, the leader in blood screening technologies. We'll save that for future editions.
There is not much to say about the trading history of the stock. The little it has traded has been in the $4 range for the last six months. I have absolutely no idea where it will trade tomorrow. It closed today at $2.50. There are 16.5 million shares I&O according to their last SEC filing. This idea is only for long term investors who want to get in on the first look at unique and exciting new biotechnology. If you like the biotech sector, a small position in this stock is a must own for the speculative end of your portfolio.
XNOM the stock to own:
Xenomics Establishes Department of Licensing and Intellectual Property, Hires Veteran Patent Agent David Ladner to Head Unit
Thursday March 24, 4:01 pm ET
Former Bayer and American Cyanamid Executive Will Direct Company's Intellectual Property and Licensing Business
NEW YORK--(BUSINESS WIRE)--March 24, 2005--Xenomics, Inc. (OTCBB:XNOM - News), a developer of next-generation medical DNA technologies, has announced the formation of a Department of Licensing and Patents to manage the growth and licensing business of the Company's expanding intellectual property portfolio. Dr. David Ladner, a patent agent and research scientist with extensive background in the pharmaceutical and chemical industries, has been hired to lead the new unit in the position of Director of Licensing and Intellectual Property.
"The continued expansion of our intellectual property portfolio and the potential for licensing revenues is central to Xenomics' strategic plans for growth and increased shareholder value," said Dr. Randy White, CEO of Xenomics. "As we move from research to commercial product development our intellectual property portfolio has already started to expand in both the U.S. and Europe. Dr. Ladner's appointment as Director of Licensing and Intellectual Property is a key addition to help us manage our growth in this crucial area."
Xenomics is developing and commercializing proprietary gateway DNA testing technology that has the potential to significantly expand the field of molecular diagnostics, currently a $1.5 billion segment of the health care and biotechnology industry. The Company is using its patented Transrenal DNA-based technology platform to develop a number of medical tests for infectious diseases including AIDS and tuberculosis, and for prenatal genetic testing, including gender determination, Rh incompatibility and Down syndrome. Xenomics' breakthrough technology enables detection of DNA using safe, simple and non-invasive urine collection, which offers a number of significant advantages over current techniques that require blood or tissue sampling.
Dr. Ladner, a longtime senior research scientist with extensive experience as a patent agent and specialist in the chemical and pharmaceutical industries, holds a Ph.D. in Organic Chemistry and is currently pursuing an MBA. He was a manager of Intellectual Property at Bayer Pharmaceutical Division for the last five years, where he handled patent filing and prosecution for Chemical Research. He also served as Patent Liaison as well as Research Manager at American Cyanamid Co., for over 20 years, overseeing key aspects of patents and intellectual property. Dr. Ladner holds 22 patents himself, and has published widely in professional journals.
"We are lucky to have someone with David's experience to guide our patent expansion and licensing business," said Dr. White. "His scientific background and technical knowledge of the patent and licensing area is a perfect combination for interaction with our scientific staff."
"I'm excited to bring my experience in patents and licensing to a company with such great potential as Xenomics," said Dr. Ladner. "I believe the company is poised to make extensive and important scientific discoveries, and I look forward to being a part of the team."
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using trans-renal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact:
Xenomics, Inc.
Randy White, 212-297-0808
or
Trilogy Capital Partners, Inc. (Investor Relations)
Paul Karon, 800-342-1467
paul@trilogy-capital.com
Source: Xenomics, Inc
NVLT,the stock to watch very closely
http://www.novelos.com/
Novelos Therapeutics, Inc. (OTC BB:NVLT.OB - News), a biotech company focusing on oxidized glutathione for use in fighting cancer and hepatitis, just announced that it has filed an orphan drug application with the U.S. FDA for the Company's lead compound, NOV-002. The application focuses on the investigation of combination therapy of NOV-002 with standard chemotherapy for treating refractory (chemotherapy resistant) ovarian cancer. A response from the FDA is expected by mid August.
Novelos Therapeutics (“NVLT”) is commercializing clinically validated pharmaceuticals for the treatment of cancer and hepatitis – huge markets with vast unmet need
http://www.wallstreetreporter.com/profiles/NovelosTherapeutics.html
http://www.ceocfointerviews.com/interviews/Novelos3.htm
Novelos Therapeutics (“NVLT”) is commercializing clinically validated pharmaceuticals for the treatment of cancer and hepatitis – huge markets with vast unmet need
Healthcare
Biotech/Pharma
(NVLT-OTC: BB)
Novelos Therapeutics, Inc.
One Gateway Center, Suite 504
Newton, MA 02458
Phone: 617-244-1616
Harry S. Palmin
President and Acting CEO
Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
June 30, 2005
BIO:
Harry S. Palmin, President and Acting CEO
Mr. Palmin has been President, CFO and Director of the Company since 1998, heading up Novelos' operations, finance, business development, as well as overseeing clinical development. Prior to joining the Company, Mr. Palmin was Vice President at Lehman Brothers from 1996 to 1998, responsible for sales, product and risk management in Private Client Services. He was an Associate at Morgan Stanley & Co. from 1993 to 1996. Mr. Palmin has a B.A. degree in Economics and Business, magna cum laude, and an M.A. degree in International Economics and Finance from the International Business School at Brandeis University. He studied at the London School of Economics and the Copenhagen Business School. Mr. Palmin is fluent in Russian and English.
Company Profile:
Novelos Therapeutics, Inc. (OTCBB: NVLT) was established in 1996 to commercialize two promising oxidized glutathione based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were developed. NOV-002, marketed in Russia by an unrelated entity under the trade name GLUTOXIM®, has been administered to over 5,000 patients, yielding excellent safety and promising efficacy data. A U.S. Phase I/II clinical trial of NOV-002 for lung cancer has been completed. The Company plans to file an IND for NOV-205 as a mono-therapy for hepatitis C and to initiate U.S. clinical trials.
CEOCFO: Mr. Palmin, what was your vision when you came to Novelos, and how has that developed?
Mr. Palmin: “I came to Novelos Therapeutics seven years ago, with a vision of commercializing clinically validated compounds for cancer and hepatitis, both huge markets with vast unmet need. Our compounds are approved for use in Russia, where many thousands of patients have already been treated, safely and effectively. A U.S. Phase I/II trial in lung cancer has already been completed with our lead compound, NOV-002, and we expect to move into a pivotal lung cancer study next year. U.S. clinical trials with NOV-205, our second compound, for hepatitis C are anticipated to commence by year-end.”
CEOCFO: Does the Russian approval shorten the US regulatory process or make it more likely to be successful?
Mr. Palmin: “Both. The Russian approval means we have safety, clinical activity in patients and well-established manufacturing process, which means we are more likely to succeed. The Russian data for NOV-002, our lead compound, was comprised of extensive preclinical safety data and controlled clinical trials in 340 cancer patients, used in combination with chemotherapy, which demonstrated safety and clinical activity. We presented this data to the US FDA, and we able to proceed with the US Phase I/II lung cancer study. We have a similar package for NOV-205, our second compound for hepatitis, which we plan to submit to the FDA this fall as part of an IND.”
CEOCFO: Will you tell us about the compounds?
Mr. Palmin: “Novelos’ compounds are based on a novel oxidized glutathione platform. Our lead product is NOV-002, which is a cytoprotectant and an immuno-modulator. This compound has been on the market in Russia for more than five years and has been in more than 5,000 patients. Taking NOV-002 in combination with toxic chemotherapy, patients in Russian clinical studies immediately began to feel better, their blood and immune indices improved, they were able to take more cycles of chemotherapy, all of which translated into a survival advantage. In fact, when used in combination with chemotherapy, NOV-002 increased the one-year lung cancer survival rate from 17% to 63% in a Russian study. The final results of the US Phase I/II study are expected in the next few weeks and we expect no surprises. Preliminary US results confirm the safety demonstrated in Russian trials. Further, patients treated with NOV-002 demonstrated a trend for higher tolerance of chemotherapy versus the control group. We expect to move into a pivotal Phase IIb/III study next year.
The clear advantages of NOV-002 are that the compound is safe, clinically validated and manufacturing is simple-inexpensive-scalable. There are currently no good treatments for late stage solid tumor cancer patients. Chemotherapy or radiation therapy are poisons, and the hope is that they kill the tumor before killing the patient. Some of the new biologics that have come on the market are not the answer – they are marginally effective, have safety issues and are very expensive – costing as much as fifteen thousand dollars per month.
In another Russian study, NOV-002 had sensitized previously resistant ovarian cancers, substantially raising the patient response rate to chemotherapy treatment. Therefore, we recently filed an orphan drug application with the U.S. FDA for NOV-002. The application focuses on the investigation of combination therapy of NOV-002 with standard chemotherapy for treating refractory (chemotherapy resistant) ovarian cancer. A response from the FDA is expected by mid August.
Animal models have shown that NOV-002 may provide a significant survival advantage if administered following catastrophic radiation exposure from, for example a nuclear weapon, a dirty bomb, or an accident at a nuclear power plant.
Our second compound, NOV-205 is being developed to treat hepatitis B and C. In Russian clinical studies, when used as mono-therapy for one month in hepatitis B and for two months in hepatitis C, NOV-205 has been shown to greatly reduce or eliminate viral loads and to vastly improve liver function relative to existing drugs on the market. We are most interested in chronic hepatitis C, which is a $2 billion marketplace currently and slated to grow to $10 billion by 2012. Therefore, we plan to file an IND with the U.S. FDA for NOV-205 as a mono-therapy for chronic hepatitis C, and to initiate U.S. clinical trials.”
CEOCFO: What do you see down the road and how do you commercialize your compounds?
Mr. Palmin: “The big picture first – you know how they say that it takes fifteen years from start to finish to bring a drug to the market, well that is true. We have been doing this for more than a decade. The Russian company was built, the compounds in Russia were commercialized, and recently we completed the U.S. Phase I/II lung cancer study. The next step is for us to meet with the FDA early next year, and then commence a pivotal Phase IIb/III lung cancer study, as well as the Phase II studies in refractory (chemotherapy resistant) ovarian cancer and chronic hepatitis C (with our second compound, NOV-205). In four years, we hope to have approval in the U.S. for the non-small cell lung cancer indication in combination with chemotherapy, followed by a year later with ovarian cancer and chronic hepatitis C.”
CEOCFO: Will you tell us about the financial picture of the company?
Mr. Palmin: “Concurrently with going public, we closed on the first round of a private placement of 2.2 million dollars. We are positioned to access the capital markets as opportunities present themselves.”
CEOCFO: Do you see partnerships ahead, and what is your strategy there?
Mr. Palmin: “Yes. We would like to have a partner by the time we begin the pivotal Phase IIb/III study in lung cancer. The idea is to defray the costs of the late stage study through partnerships in Europe as well as Japan.
On the in-licensing front, with a publicly traded currency in the form of Novelos’ common shares, we will be able to consider acquiring additional products or technologies.”
CEOCFO: Are cancer and hepatitis companies in favor?
Mr. Palmin: “I certainly think so, since we are dealing with huge markets with a vast unmet need. Lung cancer is currently a billion-dollar market place. Adding up the market for all solid tumors, we are talking about a multi billion-dollar market place. As I previously mentioned, chronic hepatitis C is a growing problem, and poorly served. The other problem with hepatitis C is that there are no predictive animal models, which also explains the lack of a drug pipeline. Anytime we have potential to address such huge patient populations with such great unmet need, that is exciting.”
CEOCFO: Why should potential shareholders be interested in Novelos?
Mr. Palmin: “Our story is simple, yet powerful. We have safety and clinical validation from many thousands of Russian patients. Now we are starting to see data come out of the U.S. We have very strong intellectual property, with patents issued in the U.S., Europe and Japan. Our manufacturing is simple, inexpensive and scalable.
Next year we expect to be a late stage, Phase IIb/III, cancer company, with Phase II studies in refractory ovarian cancer and chronic hepatitis C.”
CEOCFO: In closing, what do you expect Wall Street’s reaction will be to your promising new therapies?
Mr. Palmin: “We do not know what the stock market is going to be tomorrow. In the current choppy market, Phase I/II cancer or hepatitis companies are currently trading at $70 to 100 million market capitalizations. Once the companies get more developed, with ongoing Phase II or commencing of Phase III studies, valuations seem to be in the $300 to $400 million. Once companies get into more established Phase III type studies, they start to flirt with billion-dollar market caps. On a relative valuation basis, we expect to be commencing a pivotal Phase IIb/III lung cancer study next year and we expect to have a number of Phase II studies ongoing.
So, please look us up under symbol NVLT.”
disclaimers
Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.
“Novelos’ compounds are based on a novel oxidized glutathione platform. Our lead product is NOV-002, which is a cytoprotectant and an immuno-modulator. This compound has been on the market in Russia for more than five years and has been in more than 5,000 patients. Taking NOV-002 in combination with toxic chemotherapy, patients in Russian clinical studies immediately began to feel better, their blood and immune indices improved, they were able to take more cycles of chemotherapy, all of which translated into a survival advantage. In fact, when used in combination with chemotherapy, NOV-002 increased the one-year lung cancer survival rate from 17% to 63% in a Russian study.” - Harry S. Palmin
green baron comment about the recent research report
The Green Baron Report does its best to boil down the most important points to focus on when we choose a stock for our members. Our staff has carefully researched and combed through tremendous amounts of information and data so you won’t have to. We choose only the best of the best stock picks we can find only after careful analysis. BioCurex has an incredible story, and it could take reading over 20 pages to gain a better understanding of this Company. Well, if you feel compelled to read this type of report on BioCurex, we strongly suggest our members follow the link in the reprinted press release below and attain a copy.
In our opinion, we note that the projected target price of $2.17 is based on extremely conservative numbers. The writer of this report was not privy to information that might have caused him to significantly increase this number. We at The Green Baron Report do not have access to such numbers either, but our conversations with management and others indicate that much higher prices in the stock are anticipated and warranted.
Technically, BOCX is showing signs of improvement. The closing price of $1.24 per share is the highest close we have seen since our initial profile earlier this month at .97 per share. Stochastic indicators appear to have recently bottomed again, and the increased volume seems to support that a bigger move up is coming.
July 26, 2005 - BioCurex Inc. wishes to advise its shareholders of the availability of an independent research report on the Company prepared by Emergent Growth Analytics Research. The report strictly represents the views of the analyst concerning Biocurex. The report is available at http://www.smallcapnetwork.net/bocx_signup.html concerning BioCurex. The information may be of interest to the shareholders of BioCurex and the link to the report is provided for their benefit.
BioCurex is advancing in its corporate goals and will provide the appropriate updates. The Company is pleased to note that it is receiving increasing attention for its patented/proprietary technology for the detection of many types of cancer with a basic blood test.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. Abbott's goal is to further develop this technology, incorporating it into future tests on their ARCHITECT(r) system, for use in cancer diagnosis and monitoring.
Even a third of Aurelius royalties projections
and you have a 10 to 15$ stock (and for cancer diagnostics
alone!)
I strongly believe the risk reward at this level is compelling.
Royalties projections:
According to Arelius Consulting Group
The projections for the royalties from diagnostics exceeds $100 million once the various tests are licensed and distributed by major pharmaceutical companies.
Reasons to Consider Investing in BioCurex:
Patented and proprietary RECAF technology.
Licensing agreement with Abbott Laboratories, the world's largest diagnostics healthcare company
Technology platform for diagnostics and therapeutics
First mover advantage
Renowned scientific team
Experienced management
Favorable regulatory environment and approval process
Significant and growing markets with huge demand for the technology
Tests easily implemented by physicians
Opportunity to reduce human suffering and develop a profitable investment
smallcap network comments about thereport
BioCurex - The Word is Out.
SmallCap Digest is pleased to make available --to current as well as new subscribers-- an extremely detailed 24-page research report on the current and future prospects for one of our favorite biotech companies, BioCurex Inc (BOCX.PK).
To acquire your online copy in PDF format simply click the following link or copy and paste it in your browser: http://www.smallcapdigest.net/news_images/bocx_research_report.pdf.
Get all the facts and more…
This exhaustive report, written by Emergent Growth Analytics Director of Research Justin Frere (MBA, CPA) is de rigueur for those serious investors interested in both the amazing potential of BioCurex as well as the smallcap biotech market.
The report clearly defines BioCurex’s present market opportunities to which Mr. Frere assigns a price target/value of $2.17—representing roughly a100 percent return from recent share price levels.
More importantly, the report states:
“Our valuation does not include the potential significant revenues that might be generated if BioCurex and their licensee successfully complete immunotherapy based applications that target specific tumors and effectively immunize against or destroy cancer”.
While SmallCap Digest always brings you timely and actionable trading information, a detailed report such as this gives investors the luxury of seeing all the historical data as well as the potential for this unique and exciting company. Charts and graphics as well as comparables with more than a dozen other biotechs are included as are the hard corporate numbers.
All in all, whether you are a long-term shareholder, just coming to BioCurex, or want a definitive assessment of the company, this report is a definite ‘ must read’.
The report, while detailing BioCurex’s current RECAF™ product platform, also delineates the potential of the company’s future systemic applications such as imaging and vaccines:
“Initial systemic product candidates will most likely be targeted at the most prolific cancer types including prostate, cervical, breast, lung, colon, etc., in which treatments, cures, and diagnostics are in great demand. Accordingly, these potential product applications could represent an even greater revenue and profit opportunity for BioCurex than its diagnostic and testing applications”.
The report also discusses BioCurex’s recent semi-exclusive licensing arrangement with Abbott Labs (NYSE: ABT). The research gives opinion on both the validation gained by BOCX and the potential incorporation of its technology into Abbott’s suite of high-volume diagnostic tests:
“Recently, Abbott Laboratories licensed certain aspects of BioCurex’s serum assay technology on a semi-exclusive worldwide basis after conducting thorough testing. Abbott’s belief that RECAF™ could provide good clinical sensitivity and specificity as a tumor marker is a substantial validation of BioCurex’s technology, and we expect to see Abbott further develop the technology and incorporate it into further tests on its ARCHITECT® system for use in cancer diagnosis and monitoring”.
All in all a virtual plethora of great information. Click the link above and access your copy.
We feel that this report strongly reinforces our contention—which we first alerted the readership to in October 2003 when BioCurex was at 17 cents—that the technology and potential for the company remains extremely compelling.
As we have oft-said, the shares deserve a position in the biotech section of your portfolio for what we believe will be superior long-term gains. We’re confident that you’ll find both this report and our continued coverage of BioCurex extremely helpful in that regard.
The BioCurex press release regarding the release of the report may be viewed here:
http://biz.yahoo.com/pz/050722/82606.html
Boxcman that why i like this analysis:
worth reading carefully again
http://www.ragingbull.lycos.com/mboard/boards.cgi?board=BOCX&read=5536
By: brucebadeau
08 Apr 2005, 11:51 AM EDT
Msg. 5536 of 7900
Jump to msg. #
I want to clarify some important facts...
1. Diagnostics is a large market and Therapy is ten times the size.
2. Diagnostics is cheaper to enter, faster to generate revenue, hence BOCX's current strategy of licensing the major diagnostic companies… very necessary to employ their immense marketing muscle and their respective market shares... Ever since Technicon invented the first high speed automated blood analyzers, the world has been purchasing growing numbers of these machines that run dozens of different assays as rapidly as 8000 per hour… This is what ABBOT does and the Architect is their newest fastest machine…
3. RECAF is a molecule either produced by living cancer cells OR by dying ones, NOT by benign tumors… Tumors have a living surface with the inside essentially dead...The RECAF comes out of the cancer cell or tumor and surrounds the spaces around the cells.
4. The BOCX Patents have many claims about methods of diagnosis and therapy involving RECAF, which itself is not patented - you can't patent a naturally occurring molecule...
5. Certain anti-bodies produced by BOCX have an affinity for RECAF and will "find" the RECAF...hence "Mark" it.
6. When your PSA is elevated, it indicates something is wrong with your Prostate… likely a tumor… but is it cancerous or benign?
7. The next step required when using current, un-enhanced PSA technology is a needle biopsy (six (6) of them at $300 to $500 cost and several days of anxious waiting for results) and 3% of the patients become infected…
8. 2/3 rds of the time the screen indicates you may have cancer when (thank God) the biopsy indicates you don't...
9. Because of the very high specificity (95%) of the BOCX technology, when used with PSA screens, it could nearly eliminate the requirement for those 2/3 rds to have a needle biopsy… WHY, because benign tumors (a source of PSA) don't produce RECAF and would not be "MARKED"… by BOCX's anti-bodies.
10. Possibly, there are over 5 million PSA tests performed annually and about 230,000 confirmed cases of prostate Cancer each year in the USA. Reversing the math would indicate about 700,000 probable cases needing biopsies… (for every 100 elevations of PSA, only 33 are found to be cancerous). With BOCX technology enhancing PSA technology, at $400 per biopsy we could eliminate approximately 460,000 biopsies or, nearly $185 million or more of unnecessary tests.
11. How much more would you pay (PSA tests range between $87 to $127) to NOT have the anxiety, pain, risk of infection and the cost and achieve much better accuracy – (with PSA some cancers are missed)? Another $25 or $50…. I would…
12. My research shows a current PSA test kit costing the LABS just over $26.71 on a contract basis – high volume machines – and $48.80 on a non-contract basis – usually the low volume machine.
13. Now how much more could an ABBOTT charge for a patented technology that does a significantly better job?
14. Maybe $20 to $30 more (my guess) which could translate into $40 to $60 more at the retail price… ($87 + $40 or $127 + $60.
15. Another guesstimate… BOCX is likely to have a Royalty between 5% and 15% the industry average... using an average of 10% of $20 marginal revenue = $2.00 per test. Now I'm assuming BOCX gets royalty based on the marginal increase in revenue due to enhanced technology...
16. Maybe we can safely use $2.50 per enhanced test… allowing for price ranges and possible higher royalty rates…
17. OK, estimating 20% (Abbott's USA share) of 5,000,000 PSA test = 1,000,000 x $2.50 per test = $2,500,000 in BOCX Royalties from ABBOTT… just USA…
18. The World PSA market is double that of the USA so we can make the case that a full year of Royalties just from Abbott's suspected PSA enhancement market could top $7,000,000…
19. REMEMBER there is possibly another 40% points of the market or twice what we potentially have from ABBOTT… say the top three control 60% or 20% each. This roughly translates into another $14 million in royalties from two more licenses… or $21,000,000 in Royalty Revenue.
20. Keep in mind the operating costs of BOCX, while they are surely likely to rise, are less than $2,000,000 per year….
21. If you could own stock in a bio-tech company that showed an 80% Pre-tax margin, would you buy it…?
This royalty revenue is like having a $200,000,000 revenue company with after tax profits of $20,000,000, or $0.50 per share with 40,000,000 fully diluted shares outstanding… Maybe this company sports a 30 multiple because the total market hasn't been addressed… We get a $15 stock for just PSA alone….
I have some more analysis, and more to do, but this is enough for today…
I will say that these are best guesses – using independent inductive reasoning… I haven't addressed timing or cash flows or more importantly other huge diagnostic markets or what competitive technologies are on the horizon. Nor have I discussed the importance and prospects for collaborative research on using Box's technology to hunt cancer cells…
Remember now there are many ways to kill cancer. But they are broad spectrum… it is like killing rodents in the city dump with tactical nuclear weapons… you get all of the rats but you fry the entire city… I watched my best friend wife fade away after being diagnosed with bone cancer…Chemo just devastated her and probably killed her, just a little later than the Cancer would have… and at a huge reduction in quality of life… just awful for the family as well as the cancer patient….
BOCX technology has the potential to be a smart bomb that will target and when linked with a killer anti-body or toxin, selectively kill cancer cells… not the patient… We need more collaborative research to make this happen. How many of you shareholders have connections with major Cancer research hospitals? Have you considered inviting these connections to look at BOCX's technology and get them interested in some collaborative research?
I look forward to all of your comments,
Regards,
- - - - -
View Replies »
- - - - -
View Replies »
TO ALL LONGS:New BOCX RESEARCH REPORT! 24pages
http://www.smallcapdigest.net/news_images/bocx_research_report.pdf
congrats!
very good price.We are right at 50 DMA.It should hold before the uptrend continue.technicals are encouraging.
It's very conservative because
1-if i'm right the 10's of millions are projections only with Abott.
2-In my view,the 10's of millions are more likely closer to 50 milions than 20 millions.
bocxman,
I assume Wittenberg said revenues in the 10's of millions without any new deals,only with Abott,right?
In my opinion,this a very very conservative projection.
Bocxman,
You said:
"Let's take $20 mil in revs, and 50 mil shares outstanding, and a biotech industry standard p/e of 30. That's .38 EPS, or $11.40/share!! Now let's discount back 20% for time/risk and we get $9.12/share"
when you say revenues,you mean earnings?Not clear enough.